Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Macrophages form a major cell population in the tumor microenvironment. They can be
activated and polarized into tumor-associated macrophages (TAM) by the tumor-derived …

Importance The prevalence of early-stage non–small cell lung cancer (NSCLC) is expected
to increase with recent implementation of annual screening programs. Reliable prognostic …

In the last decade, optimized treatment for non-small cell lung cancer had lead to improved
prognosis, but the overall survival is still very short. To further understand the molecular …

Low dose computed tomography (LDCT) screening, together with the recent advances in
targeted and immunotherapies, have shown to improve non-small cell lung cancer (NSCLC) …

Rationale: Subsets of patients with early-stage lung adenocarcinoma (LUAD) have a poor
post-surgical course after curative surgery. However, biomarkers stratifying this high-risk …

Purpose: Prospectively identifying who will benefit from adjuvant chemotherapy (ACT) would
improve clinical decisions for non–small cell lung cancer (NSCLC) patients. In this study, we …

Rationale: The current tumour-node-metastasis (TNM) staging system is insufficient for
precise treatment decision-making and accurate survival prediction for patients with stage I …

Tumor cells can engage in a process called collective invasion, in which cohesive groups of
cells invade through interstitial tissue. Here, we identified an epigenetically distinct …

The ability to predict the response of a cancer patient to a therapeutic agent is a major goal
in modern oncology that should ultimately lead to personalized treatment. Existing …